Muscle Relaxant — Competitive Intelligence Brief

Muscle Relaxant (Muscle Relaxant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle relaxant. Area: Neurology / Musculoskeletal.

marketed Muscle relaxant Neurology / Musculoskeletal Small molecule

Target snapshot

Muscle Relaxant (Muscle Relaxant) — Korea University Anam Hospital. Muscle relaxants reduce muscle tension and spasticity by depressing neuromuscular transmission or central nervous system activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Muscle Relaxant TARGET	Muscle Relaxant	Korea University Anam Hospital	marketed	Muscle relaxant
Atracurium	Atracurium Besylate	Pfizer	marketed	Nondepolarizing skeletal muscle relaxant	Cholinergic receptor sites on motor end-plate	1983-01-01
Amrix	CYCLOBENZAPRINE		marketed	Muscle Relaxant	Histamine H1 receptor	1977-01-01
Ryanodex	DANTROLENE	Ph Health	marketed	Skeletal Muscle Relaxant	Ryanodine receptor 1	1974-01-01
Skelaxin	METAXALONE	Pfizer	marketed	Muscle Relaxant [EPC]		1962-01-01
Soma	CARISOPRODOL	Mylan Speciality Lp	marketed	Muscle Relaxant [EPC]		1959-01-01
Parafon Forte Dsc	CHLORZOXAZONE	Johnson & Johnson	marketed	Muscle Relaxant [EPC]	Nitric oxide synthase, endothelial	1958-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscle relaxant class)

1. Korea University Anam Hospital · 1 drug in this class
2. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class